A team of scientists, led by investigators at the Technical University of Munich (TUM), have produced a theory as to why some experimental antibody therapies for Alzheimer’s disease (AD) have failed to show efficacy in late-stage human trials. ---Subscribe to MedNous to access this article--- Research & University News
